Business
Sanofi becomes market authorization holder for Nuvaxovid® in Canada, expanding COVID-19 vaccine choices for Canadians
Sanofi today announces it has become the market authorization holder in Canada for Nuvaxovid, a non-mRNA protein-based COVID-19 vaccine. Nuvaxovid represents another step in Sanofi's commitment to building a diverse portfolio of best-in-class vaccines and addressing respiratory diseases for Canadians across their lifespan. Sanofi will make Nuvaxovid available in Canada for the fall 2026-2027 season.
About this update from Sanofi Sa
[{"type":"list","items":[{"val":[{"type":"text","content":"Nuvaxovid, a non-mRNA COVID-19 vaccine, will be made available in Canada by Sanofi for the fall 2026-2027 season","length":112,"tagName":"p"}]},{"val":[{"type":"text","content":"Provincial and territorial availability will be confirmed pending ongoing discussions and provincial assessments","length":112,"tagName":"p"}]},{"val":[{"type":"text","content":"Transfer of market authorization from Novavax follows the strategic agreement signed between the two companies in May 2024","length":122,"tagName":"p"}]},{"val":[{"type":"text","content":"This underscores Sanofi's commitment to public health and vaccine innovation in Canada","length":90,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":436,"olType":false},{"type":"text","content":"TORONTO, April 9, 2026 /CNW/ - Sanofi today announces it has become the market authorization holder in Canada for Nuvaxovid, a non-mRNA protein-based COVID-19 vaccine. Nuvaxovid represents another step in Sanofi's commitment to building a diverse portfolio of best-in-class vaccines and addressing respiratory diseases for Canadians across their lifespan. Sanofi will make Nuvaxovid available in Canada for the fall 2026-2027 season.","length":437,"tagName":"p"},{"type":"image","alt":"Sanofi (CNW Group/Sanofi-Aventis Canada Inc.)","displaySize":"","headline":null,"caption":"Sanofi (CNW Group/Sanofi-Aventis Canada Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":184,"url":"https://media.zenfs.com/en/cnwgroup.com/df9395617e2a6570aa0987f129cc22d1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/U9u5hqT5umTDtiXkn4LFBQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMyNA--/https://media.zenfs.com/en/cnwgroup.com/df9395617e2a6570aa0987f129cc22d1","width":400,"height":184}},"href":"https://mma.prnewswire.com/media/2952500/Sanofi_Aventis_Canada_Inc__Sanofi_becomes_market_authorization_h.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""With the launch of Nuvaxovid, a non-mRNA protein-based COVID-19 vaccine, Sanofi is now able to offer Canadians greater choice when it comes to COVID-19 protection. The availability of Nuvaxovid means that every Canadian will have the opportunity to access their personal COVID-19 vaccine choice," said Delphine Lansac, General Manager, Canada, Vaccines at Sanofi. "...